Racemic exo-epiboxidine 3, endo-epiboxidine 6, and the two unsaturated epiboxidine-related derivatives 7 and 8 were efficiently prepared taking advantage of a palladium-catalyzed Stille coupling as the key step in the reaction sequence. The target compounds were assayed for their binding affinity at neuronal a4b2 and a7 nicotinic acetylcholine receptors. Epiboxidine 3 behaved as a high affinity a4b2 ligand (K i = 0.4 nM) and, interestingly, evidenced a relevant affinity also for the a7 subtype (K i = 6 nM). Derivative 7, the closest analogue of 3 in this group, bound with lower affinity at both receptor subtypes (K i = 50 nM for a4b2 and K i = 1.6 lM for a7) evidenced a gain in the a4b2 versus a7 selectivity when compared with the model compound.
a4b2 and a7 nicotinic acetylcholine receptors. Epiboxidine 3 behaved as a high affinity a4b2 ligand (K i = 0.4 nM) and, interestingly, evidenced a relevant affinity also for the a7 subtype (K i = 6 nM). Derivative 7, the closest analogue of 3 in this group, bound with lower affinity at both receptor subtypes (K i = 50 nM for a4b2 and K i = 1.6 lM for a7) evidenced a gain in the a4b2 versus a7 selectivity when compared with the model compound.
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Neuronal nicotinic acetylcholine receptors (nAChRs) make up a family of pentameric ligand-gated ion channels, which are formed by combinations of alpha and beta subunits 1, 2 or exist as homopentamers, in the cases of a7, a8, and a9 receptors, which are inhibited by a-bungarotoxin. 3 To date, nine a (a2-a10) and three b (b2-b4) isoforms have been characterized, though only a relatively small subset of combinations generates functionally and physiologically relevant channels. 4 Nicotinic receptors are widely distributed in the brain, where they primarily modulate the release of other neurotransmitters and, to a lesser extent, mediate synaptic transmission. 5 Neuronal nAChRs, selectively activated by (S)-nicotine 1 (Fig. 1) , are involved in various processes such as cognition, learning and memory, cerebral blood flow and metabolism, as well as an array of pathological conditions such as Alzheimer's and Parkinson's diseases, mild cognitive impairment (MCI), schizophrenia, epilepsy, Tourette's syndrome, anxiety, depression, attention-deficit hyperactivity disorder (ADHD), and nicotine addiction.
1,2,6,7
The heteromeric a4b2 receptors, the most abundant subtype in the mammalian CNS, and the homomeric a7 channels are privileged biological targets in the search for selective nAChR ligands with therapeutic potential. 2, 8 As far as the number of nicotinic agonists isolated from natural sources is taken into consideration, 9 (À)-epibatidine 2 ( Fig. 1) , a highly toxic alkaloid identified in the skin of the Ecuadorian frog Epipedobates tricolor, 10 has inspired a huge amount of research aimed at designing subtype selective nicotinic agonists. 1, 2, 9, 11, 12 Although the pharmacological effects of (À)-2 are mediated by a variety of nAChRs, 13 which preclude any therapeutic potential for epibatidine, the analgesic potency, roughly 100 times higher than that of morphine and 30 times higher than that of nicotine, has been attributed to its high affinity for the a4b2 subtype. Worth mentioning, (À)-2 and (+)-2 are characterized by similar affinities for nAChRs and almost identical ED 50 values in the mouse tail-flick antinociception assay.
13d, 14, 15 Among the synthetic epibatidine-related compounds, (±)-epiboxidine 3 (Fig. 1) , in which the 3-methylisoxazolyl moiety has replaced the chloropyridinyl ring of the parent derivative, behaved as a potent a4b2 nicotinic receptor agonist, 10-fold less potent than epibatidine as antinociceptive agent but about 20-fold less toxic. 16 The presence of the 3-methylisoxazole ring was similarly effective in the structure of (S)-ABT-418 4 ( Fig. 1) , a nicotine-related a4b2 selective full agonist, which entered Phase I for the treatment of cognitive dysfunction and was later on discontinued. In the present study, we aimed at further investigating epiboxidine, that is, at a7 nAChRs, a subtype on which, to the best of our knowledge, it was never assayed. To this end, we thought about a flexible synthesis of (±)-3 allowing also the preparation of unsaturated structurally related derivatives. Accordingly, we describe a novel synthetic route to epiboxidine 3 (exo-isomer), its epimer endo-epiboxidine 6, and the two unprecedented dehydro-analogues of epiboxidine 7 and 8. The target chiral compounds, whose structures are reported in Figure 1 , were prepared and tested as racemates.
As illustrated in the upper part of Scheme 1, the known preparations of 3 took advantage of the reaction of 7-azabicyclo[2.2.1]heptane-2,7-dicarboxylic acid diesters 9a and 9b with the dianion of acetone oxime, followed by acidic treatment of intermediates 10a and 10b. 16, 20 As an alternative approach, we planned to make use of a Stille palladium-catalyzed cross-coupling reaction, 21 which involved the coupling of enoltriflate 11 with 3-methyl-5-tributylstannylisoxazole 12, as depicted in the lower part of Scheme 1. Initially, we made use of a known procedure to prepare 7-tertbutoxycarbonyl-7-azabicyclo[2.2.1]heptan-2-one 16, a key intermediate in one of the syntheses of (±)-epibatidine. 22 The first step of the sequence, a [4+2] cycloaddition of N-Boc-pyrrole 13, used in large excess, to methyl 3-bromopropiolate 14, was performed under microwave heating (Scheme 2). 23 These experimental conditions allowed reduction of the reaction time (from 30 to 1.5 h) and improvement of the yield of the Diels-Alder adduct 15 (from 60% to 85%). Subsequently, we prepared the known trifluoromethanesulfonate 11 24 in 62% isolated yield by treatment of ketone 16
with LDA in THF at À78°C 25 followed by reaction with N-(5-chloro-2-pyridyl)bis(trifluoromethanesulfonimide) 26 (Scheme 2).
3-Methyl-5-tributylstannylisoxazole 12 was obtained through the previously described 1,3-dipolar cycloaddition of tributylethynyltin 17 to acetonitrile oxide. 27 As a modification of the known procedure, we chose to isolate the stable precursor of the 1,3-dipole, that is, the acetohydroximoyl chloride 18, which in turn was synthesized by reacting acetaldoxime with benzyltrimethylammonium tetrachloroiodate (BTMA ICl 4 ). 28, 29 In this way, the target tributylstannylisoxazole 12 was prepared in acceptable yields (45-50%). The Stille cross-coupling reaction of triflate 11 to isoxazole 12, performed in the presence of the Tris(dibenzylideneacetone)dipalladium(0)-chloroform adduct, triphenylphosphine, and anhydrous ZnCl 2 , produced the 7-azabicyclo[2.2.1]hept-2-ene derivative 19 in 90% yield (Scheme 3). 30 Removal of the N-Boc protection of 19 with a 4 N solution of HCl in dioxane afforded the secondary amine 7, which was converted into the corresponding N-methyl derivative 8 by a standard reaction with formaldehyde followed by reduction of the intermediate aldimine with sodium cyanoborohydride. Next, hydrogenation of the carbon-carbon double bond of 19 over 10% Pd/C allowed the isolation of N-Boc-endo-epiboxidine 20 as the sole isomer in 87% yield. 31 Epimerization of 20 using potassium tert-butoxide in refluxing tert-butyl alcohol 22,31 provided the desired N-Boc-exo-epiboxidine 21 in 82% yield. The two epiboxidine epimers endo-6 and exo-3 were isolated as crystalline hydrochlorides following acidic treatment of the corresponding N-Boc protected endo-20 and exo-21 precursors, respectively (Scheme 3). Specifically, the physical and spectroscopic features of 3 hydrochloride 16 ,32 matched those of the known compound, now commercially available from Sigma. Since the hydrochlorides of 7 and 8 were amorphous salts, the free bases were reacted with a solution of fumaric acid in methanol to give rise to the corresponding 1:1 fumarates (Scheme 3). The target racemic compounds 3, 6, 7, and 8 were assayed for binding affinity at rat a4b2 and a7 nAChR subtypes, using [ In terms of binding affinity, UB-165 5, the semirigid homologue of epibatidine, showed a considerable degree of discrimination between the two neuronal nAChRs under study, the a4b2 versus a7 selectivity being higher than 10,000, due to a partially conserved affinity at the a4b2 subtype (K i = 0.27 nM) coupled with a sizeable loss of affinity at the a7 subtype (K i = 2.8 lM).
19 Also derivative 7, the unsaturated analogue of epiboxidine, was characterized by a marked drop of the affinity at the a7 subtype (K i = 1.6 lM) when compared to the parent compound. However, the presence of the double bond in 7 caused a reduction of the affinity even at the a4b2 subtype (K i = 50 nM). As a consequence, only a minor improvement of the a4b2 versus a7 selectivity (from 15 for 3 to 32 for 7) was attained. Worth noting, in terms of affinity profile at the two studied nAChRs, the results on racemic 7 are quite comparable with those obtained in the same experimental conditions for the pure isomer ABT-418. 36 At variance with the secondary amine 7, the corresponding Nmethyl derivative 8 was characterized as a low affinity unselective nicotinic ligand (K i = 0.51 lM at a4b2 and 0.39 lM at a7). A similar lack of selectivity was evidenced by endo-epiboxidine 6, which, in comparison with the exo-isomer 3, retained a non negligible affinity at both a4b2 (K i = 70 nM) and a7 (K i = 0.23 lM) nAChR subtypes. The same trend was reported at the a4b2 subtype for (±)-endo-epibatidine, 13d which exhibited a drastic reduction of affinity when compared to (±)-exo-epibatidine (K i values 7.6 and 0.035 nM, respectively), 37 coupled with the loss of the antinociceptive activity in the tail-flick test.
14 In summary, we utilized a Pd-catalyzed Stille coupling reaction as the pivotal step to prepare the two epiboxidine epimers and two unsaturated epiboxidine-related analogues. We assessed the four compounds for binding affinity at a4b2 and a7, the two major neuronal nicotinic receptor subtypes. Noteworthy, (±)-exo-epiboxidine 3 displayed a very high affinity at both nAChRs, whereas in its analogue 7 the presence of the double bond caused a loss of affinity at both subtypes together with a higher degree of a4b2 versus a7 selectivity. We will broaden the study on this set of compounds by enriching the number of unsaturated analogues and preparing the individual isomers of (±)-3 and (±)-7. The pharmacological results will be further analyzed in the light of recently developed molecular models for the two investigated receptor subtypes. 38, 39 
